Molecular Structure and Origin
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 residues, approximate molecular weight 1419.53 Da as the free acetate form), derived from a partial sequence of the BPC protein isolated from human gastric mucosa. Unlike the parent protein, BPC-157 was optimized for stability in aqueous media and resistance to proteolytic degradation. The sequence lacks disulfide bridges and contains no particularly oxidation-prone residues; this chemical stability contributes to its research utility in cell culture models and in vivo systems. Water solubility in distilled water or phosphate-buffered saline (PBS) at pH 7.4 exceeds 10 mg/mL, facilitating preparation of working solutions across concentration ranges relevant to in vitro studies (0.1–100 μg/mL) and in vivo models.
Documented Signaling Mechanisms
BPC-157 activity in preclinical models involves multiple convergent signaling pathways. The FAK (focal adhesion kinase)/paxillin pathway is the most consistently reported mechanism: BPC-157 promotes phosphorylation of FAK at Tyr397 and paxillin at Tyr118 in NIH/3T3 fibroblast cultures, with FAK autophosphorylation increases documented in the 40–80% range over control at concentrations of 1–10 μg/mL. This FAK activation is associated with enhanced cell adhesion, actin cytoskeleton reorganization, and downstream activation of Rac1/Cdc42 GTPases, which regulate actin polymerization in lamellipodia and filopodia required for directional cell migration. Concurrently, BPC-157 modulates nitric oxide (NO) signaling through upregulation of VEGFR2, with consequent eNOS (endothelial nitric oxide synthase) activation and NO production in HUVEC and EAhy926 cell lines. Studies in EAhy926 cells document NO production increases of 35–55% over control at 0.1–1 μg/mL. Activity on the Wnt/β-catenin pathway has been reported in intestinal epithelial models, with evidence of β-catenin stabilization and nuclear translocation, though these data have limited independent replication compared to the FAK/NO pathway findings.
Pharmacokinetic Profile in Animal Models
Pharmacokinetic data for BPC-157 in Sprague-Dawley rats indicate a plasma elimination half-life of approximately 15–30 minutes following intravenous bolus administration, with apparent distribution to soft tissues, liver, and intestine. Intraperitoneal administration produces Tmax of 20–40 minutes and estimated relative bioavailability of 60–80% versus IV. Oral administration, reported across several studies from the Sikiric group, maintains biological activity in gastric ulcer models at 10–100 μg/kg, though the intact absorbed fraction has not been quantified by LC-MS/MS in a manner allowing separation of active metabolite effects from parent compound activity. Typical working concentrations for in vitro studies range from 1 ng/mL to 100 μg/mL depending on the endpoint evaluated; for rat in vivo models, reported doses range from 1 μg/kg to 1 mg/kg subcutaneously or intraperitoneally.
Preclinical Data: Models and Endpoints
In vivo studies with BPC-157 in rodents span multiple injury models. In Achilles tendon transection models in Wistar rats, BPC-157-treated groups (10 μg/kg/day IP) showed significantly higher collagen fiber density versus controls at 4 weeks, with 45–60% increases in collagen cross-sectional area by histomorphometry (p<0.01). In coronary artery ligation models, BPC-157 administration reduced infarct zone (measured by TTC staining) by 30–45% versus controls at 10 μg/kg. In gastrointestinal models including ethanol-induced gastric ulcer in rats, BPC-157 at 1–10 μg/kg produced reductions of ulcerated area of 40–70% versus untreated controls. It must be noted that the majority of these studies originate from the Sikiric research group (Zagreb) with limited independent replication; interpretation of effect magnitudes should account for this methodological consideration.
Quality Parameters and Research Documentation
For reproducible research, BPC-157 must meet: ≥98% purity by HPLC-UV at 214 nm; identity confirmed by ESI-MS with [M+H]+ mass of 1420.53 ± 0.1 Da; endotoxins <1 EU/mg by LAL or rFC assay; counterion form specified (acetate preferred over TFA for cellular applications); and net peptide content (NPC) reported with Karl Fischer correction. Alpha Nordisk supplies BPC-157 under lot A26Q2BPC0612, with CoA verifiable at alphanordisk.com/verify including HPLC chromatogram, ESI-MS spectrum, and endotoxin result. For research and laboratory use. Not for unsupervised human consumption.